Advertisement

Search Results

Advertisement



Your search for ,are matches 21909 pages

Showing 801 - 850


breast cancer

Symptom-Detected Breast Cancers May Be Linked to Higher Mortality and Advanced Disease Risk

Whether a patient’s breast cancer was detected through symptoms or routine screening mammography significantly affected their risk for advanced disease or death, according to a study published recently in Radiology: Imaging Cancer. Patients with symptom-detected breast cancer had higher odds of...

Case 2: Intracranial Progression on ADC Therapy

This is Part 2 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

breast cancer
genomics/genetics

How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival

A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....

issues in oncology

Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer

Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...

issues in oncology

How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It

I’ve been a physician for several decades, seeing patients and functioning as a medical teacher; clinical, translational, and bench researcher; and administrator. Adapting to medical practice in three nations and several U.S. states has been quite challenging at different times, but I really think...

multiple myeloma

Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma

According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...

hematologic malignancies
lymphoma

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), over standard rituximab ...

issues in oncology
survivorship

Contributors to Risk of Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer

In a study reported in The Lancet Oncology, Neupane et al explored the question of whether cancer treatment and genetic predisposition are primary contributors to the risk of subsequent neoplasms (SNs) in long-term survivors of childhood cancers. Study Details The study involved data from the St....

lymphoma

FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma

On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...

lymphoma
immunotherapy

Study Identifies Key LBCL Traits Tied to Greatest Benefit From CD19 CAR T-Cell Therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center have identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19-targeted chimeric antigen receptor (CAR) T cell therapy. In the study,...

cardio-oncology

Elevated Cardiac Biomarkers Associated With Increased Cancer Risk

Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...

solid tumors
supportive care
symptom management

Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder

A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...

solid tumors
colorectal cancer

Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies

The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...

breast cancer
global cancer care

Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment

In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...

issues in oncology
legislation

Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually

The “One, Big, Beautiful” reconciliation bill making its way through Congress, which would make permanent provisions in the 2017 Tax Cuts and Jobs Act set to expire this year, includes massive cuts to Medicaid and Affordable Care Act marketplace coverage. An analysis of six potential Medicaid cuts...

breast cancer
lymphoma
issues in oncology
genomics/genetics

BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment

The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...

head and neck cancer

Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers

Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...

leukemia

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...

hematologic malignancies

Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis

Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial. This was the first U.S. trial of CAR T-cell therapy for patients with AL amyloidosis, demonstrating...

gastrointestinal cancer
cardio-oncology

Do the Benefits of Fluoropyrimidine for GI Cancers Outweigh Cardiovascular Risk?

Patients with gastrointestinal cancer treated with fluoropyrimidine chemotherapy benefit from an almost eightfold reduction in the risk of all-cause mortality, despite a slight increase in the risk for cardiovascular toxicity, according to recent findings published by Abiodun et al in JACC:...

colorectal cancer

Colorectal Cancer Screening: CT Colonography vs Stool Testing

Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology.   "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...

head and neck cancer
immunotherapy

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer

Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...

geriatric oncology
supportive care
global cancer care

Could A Telehealth Program Enhance Geriatric Cancer Care?

A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...

colorectal cancer

Reduced-Dose Chemoradiotherapy in Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al compared short-term response rates with standard- vs reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the multicenter, open-label, noncomparative trial,...

issues in oncology

CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays

Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...

supportive care
gynecologic cancers

Nomogram Model May Predict DVT Risk in Patients With Ovarian Cancer

Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society.   A number of significant independent risk factors for DVT...

lung cancer

FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) talectrectinib (Ibtrozi) for the treatment of adults with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC). Investigators reported that the agent has ...

gastrointestinal cancer

Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945

A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...

gynecologic cancers

Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings

Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...

solid tumors
gynecologic cancers
thyroid cancer
pancreatic cancer
prostate cancer
issues in oncology

Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests

Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...

solid tumors

Early-Onset Breast, Colorectal, Melanoma, Thyroid, Testicular, and Other Cancers Are on the Rise in the United States

A study by researchers at the National Cancer Institute (NCI) investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming more common among individuals younger than age 50. Although the study...

issues in oncology

Cutting Cancer Research Funding Is A Costly Gamble With Millions of Lives

“The [National Cancer Institute (NCI)] is a national treasure. If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years,” Richard J. Boxer, MD, wrote in an editorial Viewpoint published in JAMA Oncology ...

prostate cancer

AACR Statement on Former President Joseph Biden’s Cancer Diagnosis

The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...

gynecologic cancers

I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer

More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...

colorectal cancer

CRISPR-Cas9–Edited Tumor-Infiltrating Lymphocytes in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology,1 Lou et al found that autologous tumor-infiltrating lymphocytes genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in patients...

colorectal cancer

ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers

In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...

issues in oncology
breast cancer

Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women

The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...

cost of care
issues in oncology

ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care

Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...

prostate cancer

Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals

The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...

issues in oncology

How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research

Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...

issues in oncology

Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action

Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...

sarcoma
ai in oncology

Digital Histopathology and Automated Classification of Pediatric Sarcomas

With more than 50 different subtypes, pediatric soft-tissue sarcomas represent a broad category of disease. And given the rarity of these sarcomas, “it is difficult for pathologists to see a sufficient volume to gain expertise across all variants,” stated Adam Thiesen, BA, MD/PhD Candidate at UConn ...

skin cancer
ai in oncology

Pathology Machine-Learning Models and Diagnosis of Nonmelanoma Skin Cancers in Resource-Limited Settings

Artificial intelligence (AI) models, which were pretrained on vast data sets, outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, based on a session presented during the 2025 American Association for Cancer Research (AACR) Annual...

issues in oncology

Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity

Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...

lung cancer

Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...

breast cancer

Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer

“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...

skin cancer
genomics/genetics
immunotherapy

Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma

Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...

solid tumors
issues in oncology

Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis

Genetic material shed by tumors may be detected in the bloodstream 3 years prior to cancer diagnosis, according to a recent study published by Wang et al in Cancer Discovery. Study Methods and Results Researchers used highly accurate and sensitive sequencing techniques to analyze the plasma samples ...

breast cancer
cardio-oncology

Breast Cancer Radiotherapy Leads to Moderate Cardiac Function Decline Over Years

Patients with breast cancer receiving radiation therapy demonstrated moderate changes in their cardiac function over a period of several years, and patients who received a maximum left anterior descending artery dose had a modest worsening in both systolic and diastolic function, according to the...

ACS CAN Statement on Federal Cuts to Cancer Research

On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year.   The following is a statement from...

Advertisement

Advertisement




Advertisement